Use of extracellular vesicle microRNA profiles in patients with acute myeloid leukemia for the identification of novel biomarkers

• Published in: PloS one 2024-08, Vol.19 (8), p.e0306962
• Main Authors: Kang, Ka-Won, Gim, Jeong-An, Hong, Sunghoi, Kim, Hyun Koo, Choi, Yeonho, Park, Ji-Ho, Park, Yong
• Format: Article
• Language: English
• Subjects: Acute myeloid leukemia; Adult; Aged; Antibodies; Biological markers; Biomarkers; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Bone marrow; Cancer; Cell organelles; Chromatography; Correlation; Extracellular vesicles; Extracellular Vesicles - genetics; Extracellular Vesicles - metabolism; Female; Gene expression; Gene Expression Profiling; Genomes; Health aspects; Humans; Leukemia; Leukemia, Myeloid, Acute - diagnosis; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - metabolism; Leukemia, Myeloid, Acute - pathology; Male; Measurement; Medical prognosis; MicroRNA; MicroRNAs; MicroRNAs - genetics; MicroRNAs - metabolism; Middle Aged; miRNA; Molecular weight; mRNA; Network analysis; Oncology, Experimental; Pathogenesis; Patients; Plasma; Prognosis; Proteins; Ribonucleic acid; Risk groups; RNA; Size exclusion chromatography; Software; Survival
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0306962

This study aimed to establish clinically significant microRNA (miRNA) sets using extracellular vesicles (EVs) from bone marrow (BM) aspirates of patients with acute myelogenous leukemia (AML), and to identify the genes that interact with these EV-derived miRNAs in AML. BM aspirates were collected from 32 patients with AML at the time of AML diagnosis. EVs were isolated using size-exclusion chromatography. A total of 965 EV-derived miRNAs were identified in all the samples. We analyzed the expression levels of these EV-derived miRNAs of the favorable (n = 10) and non-favorable (n = 22) risk groups; we identified 32 differentially expressed EV-derived miRNAs in the non-favorable risk group. The correlation of these miRNAs with risk stratification and patient survival was analyzed using the information of patients with AML from The Cancer Genome Atlas (TCGA) database. Of the miRNAs with downregulated expression in the non-favorable risk group, hsa-miR-181b and hsa-miR-143 were correlated with non-favorable risk and short overall survival. Regarding the miRNAs with upregulated expression in the non-favorable risk group, hsa-miR-188 and hsa-miR-501 were correlated with non-favorable risk and could predict poor survival. Through EV-derived miRNAs-mRNA network analysis using TCGA database, we identified 21 mRNAs that could be potential poor prognosis biomarkers. Overall, our findings revealed that EV-derived miRNAs can serve as biomarkers for risk stratification and prognosis in AML. In addition, these EV-derived miRNA-based bioinformatic analyses could help efficiently identify mRNAs with biomarker potential, similar to the previous cell-based approach.